Teleflex announces positive data showing that the UroLift System treating lower urinary tract symptoms due to benign prostatic hyperplasia relieves enlarged prostate symptoms while preserving patients’ sexual function.

Teleflex Incorporated announced that data from two analyses of the UroLift System were presented at the American Urological Association (AUA) 2020 Virtual Science event. This new multimedia reinvention of the AUA 2020 poster and podium sessions was designed to connect and educate participants who are unable to gather as a result of the COVID-19 pandemic. Results from the analyses highlight the effectiveness of the minimally invasive treatment for benign prostatic hyperplasia (BPH) in preserving sexual function* and in a real-world setting.

Results from a meta-analysis of patients’ sexual function following treatment with the UroLift System versus medical therapy were presented by Claus Roehrborn, M.D., University of Texas Southwestern Medical Center. The analysis compared sexual function outcomes in 849 sexually active men from the MTOPS (Medical Therapy of Prostatic Symptoms) study who received daily treatment with an alpha blocker, 5-alpha-reductase inhibitor, either alone or in combination and 190 men from combined clinical studies of the UroLift System (L.I.F.T. pivotal trial; L.I.F.T. Crossover study; MedLift study) at 12, 24, 36 and 48 months. Results from the analysis showed that patients treated with the UroLift System experienced significant improvements in ejaculatory function and erectile function at 12 and 24-months post-treatment. Patients also reported significant improvement in overall sexual satisfaction through 48 months post-treatment.

In contrast, none of the medical therapies significantly improved patients’ erectile or ejaculatory function at any timepoint, and some therapies significantly reduced function. Patients taking finasteride reported a significant reduction in erectile function at 48 months, and patients that received a combination drug therapy experienced a significant reduction in ejaculatory function at 12 and 24 months. The analysis revealed the UroLift System treatment was superior to finasteride and combination drug therapy at preserving erectile function at 12 and 24 months. Additionally, the UroLift System significantly outperformed all three medical therapies across all timepoints at preserving patients’ ejaculatory function. Only patients who received the UroLift System reported significant improvement in overall satisfaction in sexual life.

The RWR study gathered data from 3,226 patients that were treated with the UroLift System across 22 international sites. For the analysis, patients from the real-world study were divided into non-urinary retention and urinary retention groups.
Results from the analysis showed patients from all groups experienced similar absolute International Prostate Symptom Score (IPSS) scores at all timepoints following treatment with the UroLift System. Analyses also revealed equivalent safety profiles among non-urinary retention and urinary retention patient groups from the real-world study when compared to corresponding groups in controlled studies. Finally, the results indicated that the majority of retention patients became catheter independent at the end of the studies – 84% in the RWR study and 73% in the P.U.L.S.A.R study.